pyrazines has been researched along with Peripheral Nerve Diseases in 145 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 38 (26.21) | 29.6817 |
| 2010's | 106 (73.10) | 24.3611 |
| 2020's | 1 (0.69) | 2.80 |
| Authors | Studies |
|---|---|
| Resham, K; Sharma, SS | 1 |
| Egashira, N; Yamamoto, S | 1 |
| Ma, J; Shao, ZH; Wang, YH; Zhang, LL | 1 |
| Chen, J; Lin, J; Zeng, Z | 1 |
| Aldini, G; Altomare, A; Fusi, C; Geppetti, P; Lodovici, M; Materazzi, S; Nassini, R; Patacchini, R; Trevisan, G | 1 |
| Akaogi, T; Fuchida, S; Hatsuse, M; Horiike, S; Iwai, T; Kamitsuji, Y; Kaneko, H; Kawata-Iida, E; Kobayashi, T; Kobayashi, Y; Kuroda, J; Matsumoto, Y; Murakami, S; Nakao, M; Okano, A; Shimazaki, C; Shimizu, D; Takahashi, R; Taniwaki, M; Tsutsumi, Y; Uchiyama, H; Uoshima, N | 1 |
| Caballero, D; Caballero-Velázquez, T; Castilla-Llorente, C; Encinas, C; Heras, I; López-Corral, L; Martino, R; Pérez-Simón, JA; Rosiñol, L; Sampol, A; San Miguel, J; Serrano, D | 1 |
| Brioli, A; Cavo, M; Mancuso, K; Pantani, L; Perrone, G; Pezzi, A; Rocchi, S; Tacchetti, P; Tosi, P; Zamagni, E; Zannetti, BA | 1 |
| Egashira, N; Oishi, R | 1 |
| Beppu, M; Fujimaki, Y; Isose, S; Iwai, Y; Kuwabara, S; Misawa, S; Mitsuma, S; Nakaseko, C; Nasu, S; Ohmori, S; Ohwada, C; Sekiguchi, Y; Shibuya, K; Shimizu, N; Takeda, Y | 1 |
| Dimopoulos, MA; García-Sanz, R; Gavriatopoulou, M; Gika, D; Kartasis, Z; Kastritis, E; Kyrtsonis, MC; Leleu, X; Merlini, G; Michalis, E; Morel, P; Palladini, G; Sonneveld, P; Tedeschi, A | 1 |
| Bardini, M; Carozzi, VA; Cavaletti, G; Chiorazzi, A; Dorsey, SG; Fazio, G; Meregalli, C; Oggioni, N; Quartu, M; Renn, CL; Sala, B; Serra, MP; Shanks, K | 1 |
| Comenzo, R; Cossor, F; Fallo, S; Kaul, E; Klein, A; Miller, K; Shah, G; Smith, H; Sprague, K | 1 |
| Akria, L; Azoulay, D; Ben-Yehuda, D; Braester, A; Gatt, ME; Horowitz, N; Lavie, D; Perlman, R; Suriu, C | 1 |
| Bennett, DL; Canta, A; Carozzi, VA; Cavaletti, G; Ceresa, C; Chiorazzi, A; Colombo, M; Foudah, D; La Russa, F; Marmiroli, P; Meregalli, C; Miloso, M; Nicolini, G; Oggioni, N; Sala, B | 1 |
| Benevolo, G; Boccadoro, M; Bringhen, S; Cavo, M; Di Raimondo, F; Falcone, AP; Franceschini, L; Gaidano, G; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Magarotto, V; Marasca, R; Mina, R; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, ID; Zambello, R | 1 |
| Cui, Y; Huang, ZZ; Li, D; Liu, XG; Pang, RP; Su, YM; Wei, JY; Xin, WJ; Xue, Z; Zhang, J | 1 |
| Bonnet, A; Bourcier, J; Chauvin, C; Lok, A; Mahé, B; Mocquard, J; Moreau, P; Redelsperger, L; Thomaré, P; Touzeau, C | 1 |
| Chairopoulos, K; Kilindireas, K; Koulieris, E; Koutra, E; Kyrtsonis, MC; Maltezas, D; Pangalis, GA; Pessach, I; Sachanas, SP; Tzenou, T; Zaroulis, CK | 1 |
| Höke, A; Ray, M | 1 |
| Cavalli, M; Chiarenza, A; Conticello, C; Cunsolo, R; Di Raimondo, C; Di Raimondo, F; Palumbo, GA; Romano, A; Vetro, C | 1 |
| Boccadoro, M; Bringhen, S; Desai, A; Di Raimondo, F; Esseltine, DL; García-Sanz, R; Lahuerta, JJ; Larocca, A; Londhe, A; Mateos, MV; Oriol, A; Palumbo, A; Richardson, PG; San Miguel, JF; van de Velde, H | 1 |
| Cho, J; Kang, D; Kim, K; Kim, SJ; Lee, JY | 1 |
| Badros, AZ; Bao, T; Dorsey, SG; Goloubeva, O; Hester, L; Lao, L; Lapidus, R; Medeiros, M; Pelser, C; Porter, N; Primrose, J; Sadowska, M | 1 |
| Boi, M; Carozzi, VA; Cavaletti, G; Chiorazzi, A; Del Fiacco, M; Dorsey, SG; Marmiroli, P; Melis, T; Meregalli, C; Picci, C; Poddighe, L; Quartu, M; Renn, CL; Serra, MP | 1 |
| Alexanian, R; Badillo, M; Chen, Y; Chiang, J; Cohen, L; Delasalle, K; Garcia, MK; Green, V; Guo, Y; Lee, R; Orlowski, RZ; Romaguera, J; Shah, J; Thomas, S; Wang, M; Weber, D; Wei, Q; You, B; Zhang, L; Zhou, Y | 1 |
| Dougherty, PM; Robinson, CR; Zhang, H | 2 |
| Ashcroft, AJ; Bird, JM; Brown, JM; Cairns, DA; Cavenagh, J; Cavet, J; Chalmers, A; Cook, G; Drayson, MT; Fletcher, M; Hunter, H; Morris, TC; O'Connor, S; Parrish, C; Snowden, JA; Williams, C; Yong, K | 1 |
| Moreau, P; Touzeau, C | 1 |
| Numata, H; Ohgiya, D; Sasao, T; Suyama, T; Tsuboi, K; Tsuchiya, T; Watanabe, S | 1 |
| Choi, DR; Han, B; Jung, JY; Kim, HJ; Kim, HY; Zang, DY | 1 |
| Ba-Mancini, A; Comenzo, RL; Duh, MS; Gravel, J; Knopf, KB; Lafeuille, MH; Lefebvre, P; Ma, E; Niculescu, L; Shi, H | 1 |
| Choi, YJ; Eom, KS; Jo, DY; Joo, YD; Kang, HJ; Kim, BS; Kim, CS; Kim, JS; Kim, SH; Kim, SJ; Kim, YJ; Kim, YS; Kwak, JY; Lee, JJ; Min, CK; Mun, YC; Park, CY; Park, JS; Suh, C; Yoon, SS | 1 |
| Azadeh, N; Fonseca, R; Kelemen, K | 1 |
| Fu, W; Hou, J; Huang, H; Peng, L; Zhang, C; Zhou, L | 1 |
| Argyriou, AA; Bruna, J; Cavaletti, G; Kalofonos, HP; Kyritsis, AP | 1 |
| Chung, MH; Kim, HS; Kim, I; Kim, KS; Koh, Y; Kwon, JH; Lee, SY; Park, S; Suh, SY; Yoon, SS | 1 |
| Bianchi, E; Cerretani, D; Ghelardini, C; Menicacci, C | 1 |
| Baldini, L; Cavaletti, G; Cavo, M; Elice, F; Galli, M; Gozzetti, A; Lazzaro, A; Martello, M; Montefusco, V; Palumbo, A; Pantani, L; Peccatori, J; Petrucci, MT; Pezzi, A; Rocchi, S; Ruggieri, M; Tacchetti, P; Terragna, C; Tosi, P; Zamagni, E | 1 |
| Asimakopoulos, F; Callander, N; Campbell, T; Eickhoff, J; Go, R; Hegeman, R; Hematti, P; Hutson, P; Longo, W; Markovina, S; Miyamoto, S; Williams, E | 1 |
| Martin, TG | 1 |
| Koeppen, S | 1 |
| Chu, SH; Cleeland, CS; Geng, Y; Lee, ES; Lee, YJ; Wang, XS | 1 |
| Shibayama, H | 1 |
| Anderson, KC; Dimopoulos, MA; Moreau, P; Richardson, PG | 1 |
| Yakovlev, AA; Yakovleva, MV | 1 |
| Colson, K | 1 |
| Ishida, T | 1 |
| Cho, Y; Fujisawa, F; Hori, M; Kamoshita, M; Katsura, Y; Kojima, H; Komeno, T; Kudo, D; Mukai, HY; Okoshi, Y; Ota, I; Sasaki, K; Shimizu, S; Shinagawa, A; Tanaka, K; Yoshida, C | 1 |
| Argyriou, AA; Iconomou, G; Kalofonos, HP | 1 |
| Auran-Schleinitz, T; Blaise, D; Bouabdallah, R; Coso, D; de Collela, JM; de Lavallade, H; El-Cheikh, J; Gastaut, JA; Mohty, M; Stoppa, AM | 1 |
| Auguet, M; Chabrier, PE; Favre-Guilmard, C; Prevost, G; Soulard, C; Touvay, C; Zeroual-Hider, H | 1 |
| Colvin, LA; Fallon, M; Fleetwood-Walker, SM; Johnson, PR; Mitchell, R | 1 |
| Amato, AA; Anderson, KC; Ben-Yehuda, D; Bladé, J; Boccadoro, M; Boral, AL; Cavenagh, JD; Esseltine, DL; Facon, T; Goldschmidt, H; Harousseau, JL; Lonial, S; Reece, D; Richardson, PG; San Miguel, J; Schuster, MW; Sonneveld, P; Stadtmauer, EA; Wen, PY | 1 |
| Prommer, EE | 1 |
| Cammarota, S; Cavaletti, G; Frigeni, B; Jann, S; Lanzani, F; Mattavelli, L; Petrò, D; Rossini, F | 1 |
| Borrello, I; Chaudhry, V; Cornblath, DR; Ferguson, A; Polydefkis, M | 1 |
| Caravita, T; de Fabritiis, P; Del Poeta, G; Fratoni, S; Santeusanio, G; Siniscalchi, A | 1 |
| Knopf, KB; Moretto, JC; Waller, JM | 1 |
| Amato, AA; Anderson, KC; Avigan, DE; Briemberg, HR; Chanan-Khan, AA; Doss, D; Esseltine, DL; Hassoun, H; Heffner, LT; Kesari, S; Kuter, DJ; Lonial, S; Mitsiades, C; Munshi, NC; Oaklander, AL; Richardson, PG; Schlossman, RL; Weller, E; Wen, PY; Xie, W | 1 |
| Corso, A; Lazzarino, M; Mangiacavalli, S; Pascutto, C; Varettoni, M; Zappasodi, P | 1 |
| Avezza, F; Canta, A; Carozzi, VA; Cavaletti, G; Ceresa, C; Chiorazzi, A; Crippa, L; Gilardini, A; Marmiroli, P; Meregalli, C; Oggioni, N | 1 |
| Focosi, D | 1 |
| Chang, DZ; Chiang, J; Delasalle, K; Fang, W; Forman, A; Garcia, MK; Guo, Y; Lu, J; Romaguera, J; Wang, M; Yi, Q; Zhou, Y | 1 |
| Baldini, L; Boccadoro, M; Bringhen, S; Callea, V; Casulli, AF; Catalano, L; Cavo, M; Ciolli, S; Di Raimondo, F; Galimberti, S; Gentile, M; Mannina, D; Mele, G; Morabito, F; Musto, P; Offidani, M; Palmieri, S; Palumbo, A; Petrucci, MT; Pinotti, G; Piro, E; Tosi, P | 1 |
| Alessandrino, EP; Barbarano, L; Bernasconi, P; Cafro, AM; Carella, AM; Corso, A; Grillo, G; Lazzarino, M; Mangiacavalli, S; Montalbetti, L; Morra, E; Pascutto, C; Spriano, M; Varettoni, M | 1 |
| Gay, F; Palumbo, A | 1 |
| Alden, CL; Cardoza, K; Csizmadia, E; Csizmadia, V; Fedyk, ER; Gallacher, M; Kadambi, VJ; O'Brien, L; Raczynski, A; Silverman, L; Simpson, C | 1 |
| El-Cheikh, J; Harousseau, JL; Mohty, B; Mohty, M; Moreau, P; Yakoub-Agha, I | 1 |
| Anderson, K; Laubach, JP; Mitsiades, C; Richardson, PG; Schlossman, RL | 1 |
| Anderson, KC; Badros, A; Chuma, S; Ghobrial, IM; Harris, B; Hong, F; Kunsman, J; Leduc, R; Matous, J; Padmanabhan, S; Richardson, PG; Rourke, M; Sam, A; Treon, SP; Warren, D; Weller, E | 1 |
| Alé, A; Bruna, J; Monbaliu, J; Navarro, X; Silverman, L; Udina, E; Vilches, JJ; Vynckier, A | 1 |
| Bruna, J; Clapés, V; Navarro, X; Petit, J; Velasco, R; Verdú, E | 1 |
| Aisa, Y; Iwabuchi, M; Kakimoto, T; Mihara, A; Nakazato, T; Sanada, Y; Suzuki, K | 1 |
| Mateos, MV | 2 |
| Cavaletti, G; Jakubowiak, AJ | 1 |
| Fujieda, A; Ishibashi, M; Iwamoto, T; Katayama, N; Masuya, M; Okuda, M | 1 |
| Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Cavalli, M; Cavo, M; De Rosa, L; Evangelista, A; Falcone, AP; Gaidano, G; Gentili, S; Genuardi, M; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Liberati, AM; Musto, P; Nozzoli, C; Palumbo, A; Patriarca, F; Ria, R; Rizzo, V; Rossi, D | 1 |
| Coyne, PJ; Dodson, P; Parker, GL; Ramakrishnan, V; Smith, TJ | 1 |
| Berno, T; Briani, C; Campagnolo, M; Zambello, R | 1 |
| Jang, SY; Jung, J; Lee, HK; Park, HT; Seo, SY; Shin, YK; Suh, DJ | 1 |
| Bossi, M; Canta, A; Carozzi, VA; Cavaletti, G; Chiorazzi, A; Marmiroli, P; Meregalli, C; Oggioni, N; Sala, B | 1 |
| Bertsch, U; Broyl, A; Corthals, SL; de Knegt, Y; Durie, BG; el Jarari, L; Goldschmidt, H; Jongen, JL; Kuiper, R; Lokhorst, HM; Sonneveld, P; van der Holt, B; van Duin, M | 1 |
| Cakana, A; Deraedt, W; Dimopoulos, MA; Esseltine, DL; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Richardson, PG; San Miguel, JF; Schlag, R; Shpilberg, O; Spicka, I; Van De Velde, H; Wu, KL | 1 |
| Bonnefous, C; Hassig, CA; Nguyen, PM; Noble, SA; Payne, JE; Rao, TS; Rix, P; Rozenkrants, N; Sablad, M; Shiau, AK; Smith, ND; Symons, KT; Wang, L; Yazdani, N; Zhang, Y | 1 |
| Bladé, J; Delforge, M; Dimopoulos, MA; Facon, T; Kropff, M; Ludwig, H; Palumbo, A; San-Miguel, JF; Sonneveld, P; Van Damme, P | 1 |
| Richardson, PG | 1 |
| Anderson, K; Laubach, J; Richardson, P | 1 |
| Blake, J; Brandner, S; D'Sa, S; Elliott, KJ; Lunn, MP; Rabin, N; Reilly, MM; Saifee, TA; Yong, KL | 1 |
| Broderick, E; Favis, R; Harousseau, JL; Levey, L; Meyers, M; Mulligan, G; Ricci, DS; Richardson, PG; Sun, Y; van de Velde, H | 1 |
| Borrello, I; Ferguson, A; Ghosh, N; Huff, CA; Ye, X | 1 |
| Cavaletti, G | 1 |
| Li, YC; Liao, AJ; Liu, ZG; Wang, HH; Wang, HT; Wu, B; Yang, W; Yao, K; Zhang, R | 1 |
| Arnulf, B; Cavet, J; Deraedt, W; Esseltine, DL; Feng, H; Girgis, S; Grishunina, M; Grosicki, S; Harousseau, JL; Karamanesht, I; Kropff, M; Leleu, X; Masliak, Z; Moreau, P; Pylypenko, H; Rekhtman, G; Robak, T; Shubina, A; van de Velde, H | 1 |
| Abe, M; Amou, H; Fujii, S; Harada, T; Hiasa, M; Kagawa, K; Matsumoto, T; Miki, H; Nakamura, S; Nakano, A; Oda, A; Ozaki, S; Takeuchi, K; Watanabe, T | 1 |
| Fingerle-Rowson, G; Goldschmidt, H; Ho, AD; Neben, K; Pham, M; Schmitt, S; Storch-Hagenlocher, B | 1 |
| Boyette-Davis, JA; Cata, JP; Dougherty, PM; Driver, LC; Kennedy, WR; Wendelschafer-Crabb, G; Zhang, H | 1 |
| Bladé, J; Cakana, A; Comenzo, RL; Dubrey, SW; Elsayed, Y; Enny, C; Fermand, JP; Hassoun, H; Heffner, LT; Hegenbart, U; Liu, X; Merlini, G; Mortimer, S; Palladini, G; Ramaswami, P; Reece, DE; Sanchorawala, V; Van De Velde, H; Vescio, RA | 1 |
| Avet-Loiseau, H; Corthals, SL; Goldschmidt, H; Hajek, R; Johnson, DC; Kuiper, R; Magrangeas, F; Morgan, GJ; Sonneveld, P; van der Holt, B | 1 |
| Blank, J; Callander, NS; Chang, JE; Choi, S; Eickhoff, JC; Gilbert, LA; Huie, MS; Kahl, BS; Kim, K; Longo, WL; McFarland, TA; Peterson, C; Rogers, ES; Volk, M; Werndli, JE; Yang, DT | 1 |
| Dean, J; Dickinson, M; Harrison, SJ; Januszewicz, H; Johnstone, R; Link, E; Neeson, P; Nichols, J; Prince, HM; Quach, H; Ritchie, DS; Ruell, S; Seymour, JF | 1 |
| Alé, A; Bruna, J; Jaramillo, J; Navarro, X; Udina, E; Velasco, R | 1 |
| Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, P; Hayman, S; Keith Stewart, A; Khan, ML; Kumar, SK; Lacy, MQ; Laumann, KM; Leif Bergsagel, P; Lust, J; Mikhael, JR; Reece, DE; Reeder, CB; Russell, S; Vincent Rajkumar, S; Zeldenhurst, S | 1 |
| Anderson, KC; Avet-Loiseau, H; Beksac, M; Bladé, J; Cavo, M; Chng, WJ; Comenzo, R; Delforge, M; Dimopoulos, M; Durie, BG; Einsele, H; Harousseau, JL; Jagannath, S; Jongen, JL; Lahuerta, JJ; Lee, JH; Lonial, S; Mateos, MV; Mazumder, A; Merlini, G; Miguel, JS; Moreau, P; Morgan, G; Munshi, N; Niesvizky, R; Orlowski, R; Palumbo, A; Rajkumar, SV; Richardson, PG; Sezer, O; Siegel, D; Sonneveld, P; Terpos, E; Usmani, S; Vesole, D; Voorhees, P; Wen, P | 1 |
| Berkowitz, A; Walker, S | 1 |
| Gao, Y; Long, XX; Ping, BH | 1 |
| Iida, S | 1 |
| Haensch, CA; Isenmann, S; Katona, I; Schlemmer, H; Stratogianni, A; Tosch, M; Weis, J | 1 |
| Brunetti, GA; Cartoni, C; Cupelli, L; D'Elia, GM; Efficace, F; Federico, V; Grammatico, S; Niscola, P; Petrucci, MT; Scaramucci, L; Tendas, A; Truini, A | 1 |
| Broyl, A; Jongen, JL; Sonneveld, P | 1 |
| Liu, ZG; Wang, HT; Wang, JF | 1 |
| Alloway, RR; Girnita, AL; Hanseman, DJ; Sadaka, B; Schmidt, N; Shields, AR; Walsh, RC; Woodle, ES | 1 |
| Bennett, GJ; Xiao, WH; Zheng, H | 1 |
| Argnani, L; Baccarani, M; Ballerini, F; Broccoli, A; Casadei, B; Derenzini, E; Fabbri, A; Gandolfi, L; Guarini, A; Merla, E; Pavone, V; Pellegrini, C; Puccini, B; Quintini, G; Quirini, F; Stefoni, V; Vigliotti, ML; Zinzani, PL | 1 |
| Hashimoto, N; Okamoto, S; Sadahira, K; Tsukada, Y; Ueda, T; Yokoyama, K | 1 |
| Cazzola, M; Cocito, F; Corso, A; Mangiacavalli, S; Pascutto, C; Pochintesta, L; Pompa, A | 1 |
| Akashi, K; Chong, Y; Ito, Y; Kamimura, T; Miyamoto, T; Takashima, S; Yokota, N | 1 |
| Allietta, N; Angermund, R; Bladé, J; Blau, IW; Broer, E; Corradini, P; Dimopoulos, MA; Drach, J; Giraldo, P; Mitchell, V; Petrucci, MT; Teixeira, A | 1 |
| Alsina, M; Anderson, KC; Bensinger, W; Biermann, JS; Cohen, AD; Devine, S; Djulbegovic, B; Faber, EA; Gasparetto, C; Hernandez-Illizaliturri, F; Huff, CA; Kassim, A; Krishnan, AY; Kumar, R; Liedtke, M; Meredith, R; Raje, N; Schriber, J; Shead, DA; Singhal, S; Somlo, G; Stockerl-Goldstein, K; Treon, SP; Weber, D; Yahalom, J; Yunus, F | 1 |
| Adams, J; Alexanian, R; Alsina, M; Anderson, KC; Barlogie, B; Berenson, J; Esseltine, DL; Hideshima, T; Irwin, D; Jagannath, S; Kauffman, M; Kuter, D; Lee, S; Limentani, SA; Orlowski, RZ; Rajkumar, SV; Richardson, PG; Schenkein, DP; Siegel, D; Singhal, S; Srkalovic, G | 1 |
| Meisler, AI | 1 |
| Reddy, GK | 1 |
| Colson, K; Doss, DS; Swift, R; Tariman, J; Thomas, TE | 1 |
| Crawford, CL | 1 |
| Camacho, E; Crowley, J; Durie, BG; Gabayan, E; Irwin, D; Jagannath, S; Lutzky, J; Mazumder, A; McKinley, M; Schenkein, D; Wolf, J | 1 |
| Chaudhry, V; Umapathi, T | 1 |
| Leblond, V | 1 |
| Bladé, J; Boccadoro, M; Cavenagh, J; Glasmacher, A; Jagannath, S; Lonial, S; Ludwig, H; Orlowski, RZ; San Miguel, J; Sonneveld, P | 1 |
| De Raeve, H; Lambert, J; Rombouts, S; Schroyens, W; Van de Velde, A; Van de Voorde, K; Van Regenmortel, N | 1 |
| Alexanian, R; Alsina, M; Amato, AA; Anderson, KC; Barlogie, B; Berenson, J; Briemberg, H; Esseltine, D; Irwin, D; Jagannath, S; Limentani, S; Najarian, K; Orlowski, RZ; Rajkumar, SV; Richardson, PG; Schuster, M; Siegel, DS; Singhal, S; Srkalovic, G; Wen, PY | 1 |
| Devereux, S; Gupta, S; Mufti, GJ; Pagliuca, A; Schey, S | 1 |
| Adjei, AA; Alberts, SR; Bruzek, L; Croghan, GA; Erlichman, C; Hanson, LJ; Jatoi, A; Ma, C; Mandrekar, SJ; Pitot, HC; Reid, JM; Tan, AD; Wright, JJ | 1 |
| Esseltine, D; MacGregor-Cortelli, B; Muzzy, J; O'Connor, OA; Schenkein, D; Scher, H; Slovin, S; Stubblefield, MD; Wright, J | 1 |
| Richardson, P | 1 |
| Bossi, M; Canta, A; Cavaletti, G; Ceresa, C; D'Incalci, M; De Coster, R; Gilardini, A; Marmiroli, P; Oggioni, N; Rigamonti, L; Rodriguez-Menendez, V | 1 |
| Boccadoro, M; Bruno, B; Carnevale-Schianca, F; Corradini, P; Fanin, R; Giaccone, L; Guidi, S; Mattei, D; Milone, G; Montefusco, V; Patriarca, F; Peccatori, J; Petrucci, MT; Rotta, M; Sorasio, R | 1 |
| Goto, F; Ito, N; Obata, H; Saito, S; Sasaki, M | 1 |
| Calderoni, A; Cornu, P; Freimann, H; Olie, R | 1 |
| Akpek, G; Badros, A; Can, I; Dalal, JS; Fenton, RG; Goloubeva, O; Heyman, M; Rapoport, AP; Thompson, J | 1 |
| Kita, Y; Nakazato-Imasato, E; Tanimoto-Mori, S; Toide, K | 1 |
| Brossart, P; Freier, W; Greil, R; Kiewe, P; Kühnhardt, D; Kümmel, S; Lange, W; Lehenbauer-Dehm, S; Niederle, N; Possinger, K; Preiss, J; Regierer, A; Schippinger, W; Schmid, P; Van de Velde, H | 1 |
| Blaise, D; de Lavallade, H; El-Cheikh, J; Faucher, C; Fürst, S; Hardan, I; Michallet, M; Mohty, M; Nagler, A; Nicolini, FE; Revesz, D; Shimoni, A; Sobh, M | 1 |
| Annunziata, C; Fojo, T; Poruchynsky, MS; Robey, RW; Sackett, DL; Ward, Y | 1 |
29 review(s) available for pyrazines and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines | 2021 |
Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Doxorubicin; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Vincristine | 2013 |
[Peripheral neuropathy induced by anticancer drugs].
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cold Temperature; Drugs, Chinese Herbal; Humans; Hyperalgesia; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Pyrazines; Sensation Disorders; Vincristine; Vitamin B 12 | 2013 |
Rodent models of chemotherapy-induced peripheral neuropathy.
Topics: Animals; Antineoplastic Agents; Axons; Boronic Acids; Bortezomib; Cisplatin; Disease Models, Animal; Mice; Nerve Degeneration; Paclitaxel; Peripheral Nervous System Diseases; Pyrazines; Rats; Vincristine | 2014 |
Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Hematologic Diseases; Humans; Molecular Targeted Therapy; Multiple Myeloma; Neoplasm Proteins; Peripheral Nervous System Diseases; Pneumonia; Proteasome Inhibitors; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome | 2014 |
Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Induction Chemotherapy; Multiple Myeloma; Neoadjuvant Therapy; Neutropenia; Peripheral Nervous System Diseases; Pyrazines; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide; Treatment Outcome | 2014 |
Bortezomib-induced peripheral neurotoxicity: an update.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Incidence; Neurotoxicity Syndromes; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Risk Factors; Severity of Illness Index | 2014 |
Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Oligopeptides; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Recurrence | 2013 |
Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Humans; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review.
Topics: Amitriptyline; Anticonvulsants; Antidepressive Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Carbamazepine; Central Nervous System; Cyclohexanols; Duloxetine Hydrochloride; Epothilones; Humans; Neoplasms; Neuralgia; Oxcarbazepine; Peripheral Nervous System Diseases; Pyrazines; Taxoids; Thalidomide; Thiophenes; Venlafaxine Hydrochloride; Vinca Alkaloids | 2015 |
[Supportive care in multiple myeloma for continuing anti-myeloma therapies].
Topics: Anemia; Bone Density Conservation Agents; Bone Diseases, Metabolic; Boronic Acids; Bortezomib; Diphosphonates; Humans; Hypercalcemia; Kidney Diseases; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide | 2014 |
Current treatment landscape for relapsed and/or refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Treatment Outcome | 2015 |
Treatment-related symptom management in patients with multiple myeloma: a review.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug-Related Side Effects and Adverse Reactions; Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Multiple Myeloma; Oligopeptides; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Quality of Life; Thalidomide | 2015 |
Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Electrophysiology; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Risk Factors | 2008 |
Multiple myeloma, painful neuropathy, acupuncture?
Topics: Acupuncture Therapy; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pain; Pain Management; Peripheral Nervous System Diseases; Pyrazines; Thalidomide | 2009 |
How to treat elderly patients with multiple myeloma: combination of therapy or sequencing.
Topics: Acute Kidney Injury; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Comorbidity; Disease Management; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Myeloablative Agonists; Peripheral Nervous System Diseases; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide; Transplantation Conditioning; Venous Thrombosis | 2009 |
Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide | 2010 |
Management of treatment-related adverse events in patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disorders of Excessive Somnolence; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Venous Thromboembolism | 2010 |
Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines | 2010 |
Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Incidence; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Risk Assessment; Risk Factors; Thalidomide; Treatment Outcome | 2010 |
Multiple myeloma.
Topics: Anemia; Bone Diseases; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Proteinase Inhibitors; Humans; Hypercalcemia; Immunologic Factors; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Recurrence; Renal Insufficiency; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2011 |
Management of treatment-emergent peripheral neuropathy in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Early Diagnosis; Humans; Immunologic Factors; Incidence; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Thalidomide | 2012 |
[Multiple myeloma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Denosumab; Diphosphonates; Humans; Imidazoles; Melphalan; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisolone; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Zoledronic Acid | 2012 |
General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Quality of Life | 2012 |
[A research advance on bortezomib-induced peripheral neuropathy].
Topics: Boronic Acids; Bortezomib; Humans; Peripheral Nervous System Diseases; Pyrazines | 2012 |
Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications.
Topics: Anemia; Antineoplastic Agents; Asthenia; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Approval; Drug Monitoring; Gastrointestinal Diseases; Humans; Hypotension; Multiple Myeloma; Neutropenia; Nurse's Role; Oncology Nursing; Patient Care Planning; Patient Education as Topic; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Quality of Life; Thrombocytopenia; Water-Electrolyte Imbalance | 2004 |
Toxic neuropathy.
Topics: Animals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Epothilones; Genetic Therapy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isoxazoles; Leflunomide; Neuritis; Neuroprotective Agents; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Pyrazines; Pyridoxine; Thalidomide | 2005 |
A practical update on the use of bortezomib in the management of multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Prognosis; Pyrazines; Survival Analysis; Thrombocytopenia | 2006 |
Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2007 |
37 trial(s) available for pyrazines and Peripheral Nerve Diseases
| Article | Year |
|---|---|
[Prophylaxis of Bortezomib-Induced Peripheral Neuropathy in Patients with Multiple Myeloma by High-Dose Intravenous Mecobalamin].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Vitamin B 12; Vitamins | 2017 |
Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Cyclosporine; Drug Synergism; Female; Graft vs Host Disease; Hematologic Diseases; Humans; Immunosuppressive Agents; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Remission Induction; Reoperation; Salvage Therapy; T-Lymphocyte Subsets; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine | 2013 |
Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Humans; Immunoglobulin M; Male; Middle Aged; Peripheral Nervous System Diseases; Pyrazines; Rituximab; Survival Analysis; Treatment Outcome; Waldenstrom Macroglobulinemia | 2013 |
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide; Thrombocytopenia; Treatment Outcome | 2014 |
A pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy in patients with multiple myeloma.
Topics: Acupuncture Therapy; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytokines; Feasibility Studies; Humans; Middle Aged; Multiple Myeloma; Pain Measurement; Peripheral Nervous System Diseases; Pilot Projects; Pyrazines; Time Factors; Treatment Outcome | 2014 |
Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Electroacupuncture; Feasibility Studies; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pain Measurement; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Time Factors; Treatment Outcome | 2014 |
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label,
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Disease Progression; Doxorubicin; Female; Humans; Induction Chemotherapy; Intention to Treat Analysis; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Peripheral Nervous System Diseases; Proportional Hazards Models; Pyrazines; Recurrence; Retreatment; Salvage Therapy; Stem Cell Transplantation; Thrombocytopenia; Time Factors; Transplantation, Autologous | 2014 |
Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: a prospective multicenter study.
Topics: Adult; Biomarkers; Bone and Bones; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Peripheral Nervous System Diseases; Prospective Studies; Pyrazines; Steroids; Treatment Outcome | 2014 |
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study.
Topics: Actin Cytoskeleton; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axons; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Dexamethasone; Drug Monitoring; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neurogenesis; Peripheral Nervous System Diseases; Plasma Cells; Pyrazines; Survival Analysis; Syndecan-1; Thalidomide; Transplantation, Autologous | 2014 |
Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Netwo
Topics: Acetylcarnitine; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neurologic Examination; NF-kappa B; Nootropic Agents; Peripheral Nervous System Diseases; Pyrazines; Recurrence; Severity of Illness Index; Treatment Outcome | 2014 |
Measurement of Proteasome Activity in Peripheral Blood Mononuclear Cells as an Indicator of Susceptibility to Bortezomib-Induced Severe Neurological Adverse Events in Patients with Multiple Myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Susceptibility; Female; Follow-Up Studies; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Peripheral Nervous System Diseases; Proteasome Endopeptidase Complex; Pyrazines | 2015 |
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Protocols; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Recurrence; Statistics, Nonparametric; Survival Rate | 2009 |
Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Electrophysiology; Humans; Middle Aged; Multiple Myeloma; Neurotoxicity Syndromes; Pain Measurement; Peripheral Nervous System Diseases; Pyrazines | 2008 |
Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients.
Topics: Activities of Daily Living; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Neuralgia; Peripheral Nervous System Diseases; Pyrazines; Risk Factors | 2010 |
Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Combined Modality Therapy; Constipation; Cyclophosphamide; Dexamethasone; Diarrhea; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Infections; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Transplantation, Autologous; Treatment Outcome | 2010 |
Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Immunoglobulin M; Male; Middle Aged; Peripheral Nervous System Diseases; Pyrazines; Recurrence; Rituximab; Survival Analysis; Waldenstrom Macroglobulinemia | 2010 |
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Incidence; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
Pilot trial of a patient-specific cutaneous electrostimulation device (MC5-A Calmare®) for chemotherapy-induced peripheral neuropathy.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Pain Measurement; Peripheral Nervous System Diseases; Pilot Projects; Pyrazines; Taxoids; Transcutaneous Electric Nerve Stimulation; Treatment Outcome | 2010 |
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chi-Square Distribution; Europe; Gene Expression Profiling; Gene Frequency; Genetic Predisposition to Disease; Humans; Middle Aged; Multiple Myeloma; Neoplasm Staging; Odds Ratio; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Prospective Studies; Pyrazines; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vincristine; Young Adult | 2010 |
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Risk Factors | 2011 |
Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Treatment Outcome | 2011 |
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Blood Cells; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Europe; Humans; Infusions, Intravenous; Injections, Subcutaneous; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Recurrence; South America; Treatment Outcome | 2011 |
Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects.
Topics: Aged; Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Heart Diseases; Humans; Kidney Diseases; Liver Diseases; Male; Maximum Tolerated Dose; Middle Aged; Paraproteinemias; Peripheral Nervous System Diseases; Prospective Studies; Pyrazines; Treatment Outcome | 2011 |
Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Multiple Myeloma; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Pyrazines; Risk Factors | 2011 |
VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Peripheral Nervous System Diseases; Proportional Hazards Models; Protease Inhibitors; Pyrazines; Remission Induction; Rituximab; Treatment Outcome; Vincristine | 2011 |
A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Depsipeptides; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Secondary Prevention; Survival Analysis; Thrombocytopenia | 2011 |
Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Peripheral Nervous System Diseases; Pyrazines; Secondary Prevention; Severity of Illness Index; Survival Analysis; Thrombocytopenia | 2013 |
Higher incidence of injection site reactions after subcutaneous bortezomib administration on the thigh compared with the abdomen.
Topics: Adipose Tissue; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Incidence; Injections, Subcutaneous; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies | 2013 |
A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Europe; Female; Gastrointestinal Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Prospective Studies; Protease Inhibitors; Pyrazines; Recurrence; Salvage Therapy; Thalidomide; Thrombocytopenia; Treatment Outcome | 2013 |
A phase 2 study of bortezomib in relapsed, refractory myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemoglobins; Humans; Male; Middle Aged; Multienzyme Complexes; Multiple Myeloma; Peripheral Nervous System Diseases; Prognosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Recurrence | 2003 |
New developments with bortezomib in treating multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Division; Doxorubicin; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Liposomes; Lymphoma, Non-Hodgkin; Multiple Myeloma; Peripheral Nervous System Diseases; Polyethylene Glycols; Pyrazines; Renal Insufficiency; Treatment Outcome | 2004 |
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Stem Cell Transplantation; Survival Analysis; Treatment Outcome | 2005 |
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines | 2006 |
A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Boronic Acids; Bortezomib; Carboplatin; Disease Progression; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Severity of Illness Index; Treatment Outcome | 2007 |
Bortezomib after allografting in multiple myeloma: association between neurotoxicity and cyclosporine treatment.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclosporine; Drug Interactions; Humans; Immunosuppressive Agents; Multiple Myeloma; Neoplasm Recurrence, Local; Peripheral Nervous System Diseases; Pyrazines; Transplantation, Homologous | 2007 |
Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2007 |
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Capecitabine; Carcinoma; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Hematologic Diseases; Humans; Maximum Tolerated Dose; Peripheral Nervous System Diseases; Pyrazines; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
80 other study(ies) available for pyrazines and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Pharmacological interventions targeting Wnt/β-catenin signaling pathway attenuate paclitaxel-induced peripheral neuropathy.
Topics: Animals; Behavior, Animal; Depsipeptides; Gene Expression Regulation; Male; Paclitaxel; Peripheral Nervous System Diseases; Pyrazines; Pyridines; Rats; Rats, Sprague-Dawley; Sciatic Nerve; Wnt Signaling Pathway | 2019 |
Novel therapeutic strategy to prevent chemotherapy-induced persistent sensory neuropathy by TRPA1 blockade.
Topics: Acetanilides; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Mice; Mice, Inbred C57BL; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Purines; Pyrazines; Thioctic Acid; Transient Receptor Potential Channels; TRPA1 Cation Channel | 2013 |
The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Forecasting; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Remission Induction; Retrospective Studies; Transplantation, Autologous; Treatment Outcome; Vincristine | 2013 |
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Evaluation; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Immunologic Factors; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Thrombocytopenia; Treatment Outcome | 2014 |
Bortezomib-induced neuropathy: axonal membrane depolarization precedes development of neuropathy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Axons; Boronic Acids; Bortezomib; Female; Humans; Male; Membrane Potentials; Middle Aged; Multiple Myeloma; Neural Conduction; Peripheral Nervous System Diseases; Prospective Studies; Pyrazines; Sodium-Potassium-Exchanging ATPase | 2014 |
Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse.
Topics: Activating Transcription Factor 3; Animals; Boronic Acids; Bortezomib; Electrophysiology; Female; Mice; Mice, Inbred BALB C; Peripheral Nervous System Diseases; Pyrazines | 2013 |
Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients.
Topics: Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Diarrhea; Drug Therapy, Combination; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Thrombocytopenia | 2013 |
Bortezomib-induced peripheral neuropathy is related to altered levels of brain-derived neurotrophic factor in the peripheral blood of patients with multiple myeloma.
Topics: Aged; Boronic Acids; Bortezomib; Brain-Derived Neurotrophic Factor; Female; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines | 2014 |
Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line; Ganglia, Spinal; Neurons; Peripheral Nervous System Diseases; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats, Wistar; Sciatic Nerve; Tubulin | 2014 |
TNF-α-mediated JNK activation in the dorsal root ganglion neurons contributes to Bortezomib-induced peripheral neuropathy.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Ganglia, Spinal; Hyperalgesia; JNK Mitogen-Activated Protein Kinases; Male; Mice, Inbred C57BL; Neurons; Peripheral Nervous System Diseases; Pyrazines; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha | 2014 |
Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Prospective Studies; Pyrazines; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2014 |
Assessment of bortezomib induced peripheral neuropathy in multiple myeloma by the reduced Total Neuropathy Score.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neurologic Examination; Peripheral Nervous System Diseases; Pyrazines; Risk Factors | 2014 |
Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Polyethylene Glycols; Pyrazines; Recurrence; Salvage Therapy; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2014 |
Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Humans; Melphalan; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Retrospective Studies; Treatment Outcome | 2014 |
Impact of dose modification on intravenous bortezomib-induced peripheral neuropathy in multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Patient Outcome Assessment; Peripheral Nervous System Diseases; Pyrazines | 2014 |
Bortezomib treatment produces nocifensive behavior and changes in the expression of TRPV1, CGRP, and substance P in the rat DRG, spinal cord, and sciatic nerve.
Topics: Animals; Behavior, Animal; Boronic Acids; Bortezomib; Calcitonin Gene-Related Peptide; Disease Models, Animal; Female; Ganglia, Spinal; Gene Expression Regulation; Nerve Tissue Proteins; Nociception; Peripheral Nervous System Diseases; Pyrazines; Rats; Rats, Wistar; Sciatic Nerve; Spinal Cord; Substance P; TRPV Cation Channels | 2014 |
Astrocytes, but not microglia, are activated in oxaliplatin and bortezomib-induced peripheral neuropathy in the rat.
Topics: Animals; Antineoplastic Agents; Astrocytes; Boronic Acids; Bortezomib; Glial Fibrillary Acidic Protein; Hyperalgesia; Male; Microglia; Minocycline; Neuroprotective Agents; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Pyrazines; Rats, Sprague-Dawley; Spinal Cord; Spinal Nerves | 2014 |
Altered discharges of spinal neurons parallel the behavioral phenotype shown by rats with bortezomib related chemotherapy induced peripheral neuropathy.
Topics: Action Potentials; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Models, Animal; Dose-Response Relationship, Drug; Hyperalgesia; Lumbar Vertebrae; Male; Motor Activity; Neurons; Pain Threshold; Peripheral Nervous System Diseases; Physical Stimulation; Pyrazines; Rats, Sprague-Dawley; Spinal Cord; Temperature; Touch | 2014 |
New data on subcutaneous bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines | 2015 |
An acceptable incidence of infusion site reactions after subcutaneous bortezomib administration in the upper arm in Japanese patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arm; Boronic Acids; Bortezomib; Humans; Incidence; Injections, Subcutaneous; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Severity of Illness Index | 2015 |
The positive effects of one-hour intravenous administration of bortezomib on peripheral neuropathy in multiple myeloma patients.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines | 2014 |
Amitriptyline-induced agranulocytosis with bone marrow confirmation.
Topics: Agranulocytosis; Amitriptyline; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Diagnosis, Differential; Febrile Neutropenia; Female; Filgrastim; Fractures, Spontaneous; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Multiple Myeloma; Osteolysis; Peripheral Nervous System Diseases; Pyrazines; Recombinant Proteins; Urinary Tract Infections | 2014 |
Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients.
Topics: Aged; Anticonvulsants; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Asian People; Boronic Acids; Bortezomib; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Treatment Outcome | 2014 |
Spinal administration of mGluR5 antagonist prevents the onset of bortezomib induced neuropathic pain in rat.
Topics: Analgesics; Animals; Boronic Acids; Bortezomib; Ceftriaxone; Cell Line, Tumor; Cell Survival; Central Nervous System Agents; Disease Models, Animal; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Hyperalgesia; Injections, Spinal; Male; Neural Conduction; Neuralgia; Peripheral Nervous System Diseases; Pyrazines; Pyridines; Random Allocation; Rats; Receptor, Metabotropic Glutamate 5 | 2014 |
[Clinical features of peripheral neuropathy in paraproteinemic hemoblastosis].
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Neoplasms, Plasma Cell; Peripheral Nervous System Diseases; Polyneuropathies; Pyrazines | 2014 |
[Complications and managements in treatment of melphalan, prednisone and new agents].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Molecular Targeted Therapy; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide | 2015 |
Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Retrospective Studies; Risk Factors; Salvage Therapy; Survival Rate; Thalidomide | 2008 |
The novel inhibitor of the heterotrimeric G-protein complex, BIM-46187, elicits anti-hyperalgesic properties and synergizes with morphine.
Topics: Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Constriction, Pathologic; Cyclohexanes; Drug Synergism; Edema; Heterotrimeric GTP-Binding Proteins; Hyperalgesia; Male; Morphine; Pain Measurement; Peripheral Nervous System Diseases; Psychomotor Performance; Pyrazines; Rats; Rats, Sprague-Dawley | 2008 |
From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Male; Menthol; Middle Aged; Multiple Myeloma; Pain; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; TRPM Cation Channels | 2008 |
Topical analgesic combinations for bortezomib neuropathy.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Amines; Analgesics; Boronic Acids; Bortezomib; Clonidine; Cyclohexanecarboxylic Acids; Drug Combinations; Excitatory Amino Acid Antagonists; Gabapentin; gamma-Aminobutyric Acid; Gels; Humans; Ketamine; Male; Middle Aged; Pain Measurement; Paraproteinemias; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Walking | 2009 |
Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Electrophysiology; Female; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Prevalence; Pyrazines; Thalidomide | 2008 |
Cutaneous involvement in multiple myeloma and bortezomib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Immunoglobulin A; Melphalan; Multiple Myeloma; Myeloma Proteins; Paresthesia; Peripheral Nervous System Diseases; Plasma Cells; Prednisone; Pyrazines; Remission Induction; Skin; Thalidomide; Xerophthalmia | 2009 |
Multiple significant bortezomib-related toxicities in one patient: case report and literature review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Humans; Male; Multiple Myeloma; Pain; Peripheral Nervous System Diseases; Pruritus; Pyrazines; Testis | 2009 |
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Peripheral Nervous System Diseases; Polyneuropathies; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Treatment Outcome | 2009 |
Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats.
Topics: Animals; Antineoplastic Agents; Behavior, Animal; Blood Cell Count; Blood Chemical Analysis; Body Weight; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Hot Temperature; Neural Conduction; Neurotoxicity Syndromes; Pain; Pain Measurement; Peripheral Nervous System Diseases; Pyrazines; Rats; Rats, Wistar; Sciatic Nerve | 2010 |
Bortezomib: the subtle line between drug-induced peripheral neuropathy and post-herpetic neuralgia.
Topics: Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neuralgia, Postherpetic; Peripheral Nervous System Diseases; Pyrazines | 2009 |
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cardiovascular Diseases; Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Gastrointestinal Diseases; Glomerular Filtration Rate; Hematologic Diseases; Humans; Italy; Kidney Diseases; Male; Melphalan; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Proteins; Peripheral Nervous System Diseases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Retrospective Studies; Survival Analysis; Thalidomide | 2010 |
Effect of proteasome inhibitors with different chemical structures on the ubiquitin-proteasome system in vitro.
Topics: Acetylcysteine; Animals; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Immunohistochemistry; Inhibitory Concentration 50; Mice; Mice, Inbred BALB C; Oligopeptides; PC12 Cells; Peripheral Nervous System Diseases; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Ubiquitin | 2010 |
Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Asthenia; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Prognosis; Pyrazines; Risk Management; Risk Reduction Behavior; Thalidomide | 2010 |
Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice.
Topics: Action Potentials; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Electrophysiology; Female; Ganglia, Spinal; Immunohistochemistry; Mice; Microscopy, Electron; Motor Neurons; Myelin Sheath; Nerve Fibers, Unmyelinated; Neural Conduction; Pain; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Sciatic Nerve; Sensory Receptor Cells; Skin; Tibial Nerve | 2010 |
Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients.
Topics: Age Factors; Antineoplastic Agents, Phytogenic; Boronic Acids; Bortezomib; Cohort Studies; Female; Humans; Incidence; L-Lactate Dehydrogenase; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neurologic Examination; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Recurrence; Risk Factors; Severity of Illness Index; Vincristine | 2010 |
[Severe bortezomib-induced peripheral neuropathy in a patient with multiple myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunoglobulin A; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Severity of Illness Index | 2010 |
Drug interaction between itraconazole and bortezomib: exacerbation of peripheral neuropathy and thrombocytopenia induced by bortezomib.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Interactions; Female; Humans; Itraconazole; Japan; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Secondary Prevention; Thrombocytopenia; Treatment Outcome | 2010 |
Lenalidomide for bortezomib-resistant multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Health Status Indicators; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Thalidomide; Treatment Failure | 2010 |
Pathological adaptive responses of Schwann cells to endoplasmic reticulum stress in bortezomib-induced peripheral neuropathy.
Topics: Adaptation, Physiological; Animals; Axons; Boronic Acids; Bortezomib; Disease Models, Animal; Endoplasmic Reticulum; Female; Macrophages; Mice; Mice, Inbred C57BL; Myelin Proteins; Myelin Sheath; Oligonucleotide Array Sequence Analysis; Peripheral Nerves; Peripheral Nervous System Diseases; Protease Inhibitors; Protein Unfolding; Pyrazines; Schwann Cells; Stress, Physiological | 2010 |
Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Body Weight; Boronic Acids; Bortezomib; Cisplatin; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Ganglia, Spinal; Mice; Mice, Inbred BALB C; Microscopy, Electron, Transmission; Nerve Fibers, Myelinated; Neural Conduction; Paclitaxel; Peripheral Nervous System Diseases; Pyrazines; Sciatic Nerve | 2010 |
Discovery of dual inducible/neuronal nitric oxide synthase (iNOS/nNOS) inhibitor development candidate 4-((2-cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one (KD7332) part 2: identification of a novel, potent, and selective
Topics: Administration, Oral; Analgesics; Animals; Cell Line; Drug Tolerance; Fluoroquinolones; Humans; In Vitro Techniques; Mice; Microsomes, Liver; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type II; Pain; Pain Measurement; Peripheral Nervous System Diseases; Protein Multimerization; Pyrazines; Rotarod Performance Test; Structure-Activity Relationship | 2010 |
Towards a better understanding of treatment-related peripheral neuropathy in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Gene Expression Profiling; Gene Frequency; Genetic Predisposition to Disease; Humans; Multiple Myeloma; Neoplasm Staging; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Pyrazines; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vincristine | 2010 |
Bortezomib-induced inflammatory neuropathy.
Topics: Boronic Acids; Bortezomib; Humans; Inflammation; Inflammation Mediators; Male; Middle Aged; Multiple Myeloma; Neural Conduction; Peripheral Nervous System Diseases; Pyrazines | 2010 |
Genetic variation associated with bortezomib-induced peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Boronic Acids; Bortezomib; Cathepsins; Clinical Trials, Phase III as Topic; CTLA-4 Antigen; Female; Genetic Association Studies; Humans; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Pyrazines; Randomized Controlled Trials as Topic; Schwann Cells; Transcription Factor 4; Transcription Factors | 2011 |
Bortezomib-induced peripheral neuropathy: facts and genes.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Gene Expression Profiling; Humans; Peripheral Nervous System Diseases; Pyrazines; Severity of Illness Index | 2011 |
[Study on mechanism of bortezomib inducing peripheral neuropathy and the reversing effect of reduced glutathione].
Topics: Animals; Boronic Acids; Bortezomib; Female; Glutathione; Peripheral Nervous System Diseases; Pyrazines; Rats; Rats, Wistar; Reactive Oxygen Species | 2011 |
Subcutaneous bortezomib: a step towards optimised drug use.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Infusions, Intravenous; Injections, Subcutaneous; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Quality of Life; Recurrence | 2011 |
Delayed treatment with vitamin C and N-acetyl-L-cysteine protects Schwann cells without compromising the anti-myeloma activity of bortezomib.
Topics: Acetylcysteine; Animals; Antineoplastic Agents; Antioxidants; Ascorbic Acid; Autophagy; Boronic Acids; Bortezomib; Cell Line; Endoplasmic Reticulum; Free Radical Scavengers; Multiple Myeloma; Neuroprotective Agents; Peripheral Nervous System Diseases; Pyrazines; Rats; Schwann Cells | 2011 |
Inflammatory autoimmune neuropathy, presumably induced by bortezomib, in a patient suffering from multiple myeloma.
Topics: Aged; Antineoplastic Agents; Autoimmune Diseases; Boronic Acids; Bortezomib; Female; Humans; Magnetic Resonance Imaging; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Pyrazines; Transplantation, Autologous; Treatment Outcome | 2011 |
Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pain; Pain Measurement; Peripheral Nervous System Diseases; Pilot Projects; Pyrazines | 2011 |
Evaluation of pre-existing neuropathy and bortezomib retreatment as risk factors to develop severe neuropathy in a mouse model.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Models, Animal; Female; Immunohistochemistry; Mice; Neurotoxicity Syndromes; Peripheral Nervous System Diseases; Pyrazines; Risk Factors | 2011 |
A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2012 |
Bortezomib-induced peripheral neuropathy in patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; Humans; Multiple Myeloma; Nursing Assessment; Oncology Nursing; Peripheral Nervous System Diseases; Practice Guidelines as Topic; Pyrazines; Severity of Illness Index | 2012 |
[Effect of omega-3 fish oil fat emulsion on the peripheral neuropathy caused by bortezomib].
Topics: Boronic Acids; Bortezomib; Fatty Acids, Omega-3; Fish Oils; Humans; Male; Middle Aged; Peripheral Nervous System Diseases; Pyrazines | 2011 |
Bortezomib-induced severe autonomic neuropathy.
Topics: Aged; Antineoplastic Agents; Autonomic Nervous System Diseases; Boronic Acids; Bortezomib; Humans; Male; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Severity of Illness Index | 2012 |
Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma.
Topics: Administration, Oral; Aged; Analgesics, Opioid; Antineoplastic Agents; Boronic Acids; Bortezomib; Delayed-Action Preparations; Humans; Middle Aged; Multiple Myeloma; Oxycodone; Peripheral Nervous System Diseases; Pyrazines; Rome | 2012 |
Prospective evaluation of the toxicity profile of proteasome inhibitor-based therapy in renal transplant candidates and recipients.
Topics: Adult; Boronic Acids; Bortezomib; Female; Graft Rejection; Humans; Kidney Transplantation; Male; Middle Aged; Peripheral Nervous System Diseases; Prospective Studies; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Thrombocytopenia | 2012 |
Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy.
Topics: Acetylcarnitine; Activating Transcription Factor 3; Adenosine Triphosphate; Analysis of Variance; Animals; Antineoplastic Agents; Axons; Boronic Acids; Bortezomib; Citrate (si)-Synthase; Disease Models, Animal; Electron Transport Complex II; Ganglia, Spinal; Hyperalgesia; Male; Mitochondria; Pain; Pain Measurement; Pain Threshold; Peripheral Nervous System Diseases; Pyrazines; Rats; Rats, Sprague-Dawley; Schwann Cells; Sciatic Nerve; Time Factors; Ubiquitin Thiolesterase | 2012 |
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Proteins; Off-Label Use; Peripheral Nervous System Diseases; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Retrospective Studies; Rituximab; Signal Transduction; Transplantation, Autologous; Treatment Outcome | 2013 |
Itraconazole may increase the risk of early-onset bortezomib-induced peripheral neuropathy.
Topics: Adult; Aged; Antifungal Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytochrome P-450 Enzyme System; Dexamethasone; Diabetes Complications; Drug Synergism; Female; Humans; Inactivation, Metabolic; Incidence; Itraconazole; Male; Middle Aged; Multiple Myeloma; Mycoses; Opportunistic Infections; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Protease Inhibitors; Proton Pump Inhibitors; Pyrazines; Retrospective Studies; Risk Factors; Salvage Therapy | 2012 |
Multiple myeloma, version 1.2013.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Humans; Hydroxamic Acids; Lenalidomide; Multiple Myeloma; Nitrogen Mustard Compounds; Oligopeptides; Peripheral Nervous System Diseases; Practice Guidelines as Topic; Pyrazines; Recurrence; Salvage Therapy; Thalidomide; Vorinostat | 2013 |
Bortezomib in multiple myeloma.
Topics: Amyloid beta-Peptides; Boronic Acids; Bortezomib; Diagnostic Techniques, Neurological; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines | 2003 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide | 2005 |
Waldenström's macroglobulinemia and bortezomib.
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Hematologic Diseases; Humans; Peripheral Nervous System Diseases; Pyrazines; Salvage Therapy; Waldenstrom Macroglobulinemia | 2005 |
Bortezomib-induced Sweet's syndrome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Erectile Dysfunction; Humans; Immunosuppressive Agents; Male; Melphalan; Methylprednisolone; Multiple Myeloma; Pain; Peripheral Nervous System Diseases; Prednisolone; Protease Inhibitors; Pyrazines; Recurrence; Sleep Initiation and Maintenance Disorders; Sweet Syndrome; Testicular Diseases | 2005 |
Life-threatening motor neurotoxicity in association with bortezomib.
Topics: Aged; Boronic Acids; Bortezomib; Critical Illness; Female; Humans; Middle Aged; Multiple Myeloma; Neurotoxicity Syndromes; Peripheral Nervous System Diseases; Pyrazines | 2006 |
An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib.
Topics: Aged; Boronic Acids; Bortezomib; Electrodiagnosis; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Nervous System Diseases; Prostatic Neoplasms; Protease Inhibitors; Pyrazines | 2006 |
Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Recurrence; Thrombocytopenia; Treatment Outcome | 2006 |
Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat.
Topics: Animals; Boronic Acids; Bortezomib; Female; Ganglia, Spinal; Microscopy, Electron; Neural Conduction; Neurons, Afferent; Neurotoxins; Peripheral Nervous System Diseases; Pyrazines; Rats; Rats, Wistar; Sciatic Nerve; Spinal Cord; Tail | 2007 |
Possible involvement of spinal noradrenergic mechanisms in the antiallodynic effect of intrathecally administered 5-HT2C receptor agonists in the rats with peripheral nerve injury.
Topics: Adrenergic alpha-2 Receptor Antagonists; Animals; Atropine; Injections, Spinal; Ligation; Male; Muscarinic Antagonists; Norepinephrine; Pain; Peripheral Nervous System Diseases; Physical Stimulation; Piperazines; Pyrazines; Rats; Rats, Wistar; Serotonin 5-HT2 Receptor Agonists; Spinal Cord; Spinal Nerves; Touch; Yohimbine | 2007 |
Daily practice use of Bortezomib in relapsed/refractory multiple myeloma. Safety/efficacy results of a compassionate use program in Switzerland.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Diarrhea; Drug Administration Schedule; Fatigue; Female; Humans; Male; Medical Oncology; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Recurrence; Switzerland; Thrombocytopenia; Treatment Outcome | 2007 |
Pharmacologic investigation of the mechanism underlying cold allodynia using a new cold plate procedure in rats with chronic constriction injuries.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Calcium Channel Blockers; Chronic Disease; Cold Temperature; Constriction, Pathologic; Disease Models, Animal; Diterpenes; gamma-Aminobutyric Acid; Male; Mexiletine; Morphine; Nerve Fibers, Unmyelinated; Pain; Pain Measurement; Peripheral Nervous System Diseases; Pregabalin; Pyrazines; Pyridines; Rats; Rats, Sprague-Dawley; Reaction Time; Sciatic Nerve; Sodium Channel Blockers; TRPV Cation Channels | 2008 |
High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Fatigue; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Retrospective Studies; Salvage Therapy; Survival Analysis; Thrombocytopenia; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2008 |
Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition.
Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Fluorescent Antibody Technique; G2 Phase; Humans; Microtubule-Associated Proteins; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Tubulin; Tubulin Modulators | 2008 |